PMID- 19075985
OWN - NLM
STAT- MEDLINE
DCOM- 20090226
LR  - 20191111
IS  - 1872-213X (Print)
IS  - 1872-213X (Linking)
VI  - 1
IP  - 3
DP  - 2007 Nov
TI  - A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy 
      of moderate-to-severe allergic asthma.
PG  - 225-31
AB  - The pathogenetic aspect of allergic bronchial asthma is characterized by airway 
      inflammation with infiltration of mast cells, basophils, eosinophils, monocytes 
      and T-helper (Th)2 lymphocytes. Most cases of asthma are atopic in nature and 
      aeroallergens such as those released by pollens, Dermatophagoides, moulds etc, 
      act as sensitizer and trigger agents which induce immune response through 
      immunoglobulin E (IgE). IgE is the key mediator of allergic inflammatory reaction 
      and plays a central role in the pathogenesis of atopic-allergic diseases such as 
      those of respiratory tract: rhinitis and bronchial asthma. Currently 
      antiinflammatory and bronchodilation treatments, with integration of other drugs 
      such as antileucotrienes, are effective for most of asthma patients, but there 
      are asthmatic subjects whose disease is incompletely controlled by inhaled or 
      systemic corticosteroids and these patients account for about 50% of the 
      healthcare costs of asthma. A novel therapeutic approach to asthma and other 
      allergic respiratory diseases involves interference in the action of IgE and IgE 
      has been viewed as a target for novel immunological drug development in asthma. 
      Monoclonal antibodies are a molecule able to interact with specific antigens and 
      represent a very interesting options for asthma treatment and their patents. 
      Omalizumab is a humanized recombinant monoclonal anti-IgE antibody developed for 
      the treatment of allergic diseases and with clear efficacy in adolescent and 
      adult patients with moderate-to-severe allergic asthma. This non-anaphylactogen 
      anti-IgE antibody inhibits IgE functions blocking free serum IgE and inhibiting 
      their binding to cellular receptors. By reducing serum IgE levels and IgE 
      receptor expression on inflammatory cells in the context of allergic cascade. 
      Omalizumab therapy is well tolerated and significantly improves symptoms, 
      reducing asthma exacerbations and the need to use high dosage of inhaled 
      corticosteroids to control disease. Moreover, omalizumab improves quality of life 
      of patients with severe persistent allergic asthma that is inadequately 
      controlled by currently available asthma medications. In conclusion omalizumab 
      represents a really new approach to the treatment of atopic asthma and may fulfil 
      an important need in patients with moderate-to-severe asthma.
FAU - D'Amato, Gennaro
AU  - D'Amato G
AD  - Division of Respiratory and Allergic Diseases, Department of Respiratory 
      Diseases, High Speciality Hospital A. Cardarelli, Naples, Italy. 
      Gdamato@qubisoft.it
FAU - Piccolo, Amedeo
AU  - Piccolo A
FAU - Salzillo, Antonello
AU  - Salzillo A
FAU - Noschese, Paolo
AU  - Noschese P
FAU - D'Amato, Maria
AU  - D'Amato M
FAU - Liccardi, Gennaro
AU  - Liccardi G
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Recent Pat Inflamm Allergy Drug Discov
JT  - Recent patents on inflammation & allergy drug discovery
JID - 101309297
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Animals
MH  - Anti-Allergic Agents/adverse effects/*therapeutic use
MH  - Anti-Asthmatic Agents/adverse effects/*therapeutic use
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/adverse effects/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Asthma/*drug therapy/immunology
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Immunoglobulin E/*immunology
MH  - Omalizumab
MH  - Patents as Topic
MH  - Severity of Illness Index
MH  - Treatment Outcome
RF  - 55
EDAT- 2007/01/01 00:00
MHDA- 2009/02/27 09:00
CRDT- 2008/12/17 09:00
PHST- 2008/12/17 09:00 [entrez]
PHST- 2007/01/01 00:00 [pubmed]
PHST- 2009/02/27 09:00 [medline]
AID - 10.2174/187221307782418900 [doi]
PST - ppublish
SO  - Recent Pat Inflamm Allergy Drug Discov. 2007 Nov;1(3):225-31. doi: 
      10.2174/187221307782418900.